Who is Oncolix, Inc.?
Oncolix is a biotech company with a cancer drug called 'Prolanta' in current development. Prolanta is currently in FDA clinical trials phase 1. https://clinicaltrials.gov/ct2/show/NCT02534922 Oncolix received Orphan Drug Status for their developmental drug Prolanta. http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html
AEPP (Advanced Environmental Petroleum Producers) controlling shareholder and Interim CEO has entered into a definitive stock purchase agreement in which Oncolix, Inc. will become the controlling shareholder on the day of closing. Due to unanticipated circumstances, the mailing of the 14F1 did not occur as anticipated and as a result, we have established new mailing date to be on or about March 23, 2017 and the date of the Board Change to occur on or about April 3, 2017 (but in no event later than 10 days after the actual mailing date).